866-997-4948(US-Canada Toll Free)

Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 102 Pages

Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leishmaniasis (Kala-Azar) Pipeline Review, H2 2016, provides an overview of the Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline landscape.

Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen and fever. Treatment includes anti-parasitic drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Leishmaniasis (Kala-Azar) Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 3, 11, 6 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 11 and 8 molecules, respectively.Leishmaniasis (Kala-Azar).

Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Leishmaniasis (Kala-Azar) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Leishmaniasis (Kala-Azar) Overview 10
Therapeutics Development 11
Pipeline Products for Leishmaniasis (Kala-Azar) - Overview 11
Pipeline Products for Leishmaniasis (Kala-Azar) - Comparative Analysis 12
Leishmaniasis (Kala-Azar) - Therapeutics under Development by Companies 13
Leishmaniasis (Kala-Azar) - Therapeutics under Investigation by Universities/Institutes 15
Leishmaniasis (Kala-Azar) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Leishmaniasis (Kala-Azar) - Products under Development by Companies 20
Leishmaniasis (Kala-Azar) - Products under Investigation by Universities/Institutes 21
Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development 22
Advinus Therapeutics Ltd 22
BioLingus AG 23
iCo Therapeutics Inc. 24
Laboratorios LETI S.L. 25
ManRos Therapeutics 26
Matinas BioPharma Holdings, Inc. 27
Nanomerics Ltd 28
Novartis AG 29
Oblita Therapeutics BVBA 30
Leishmaniasis (Kala-Azar) - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
(gentamicin sulfate + paromomycin sulfate) - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
18-MC - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
amphotericin B - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
amphotericin B - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
amphotericin B - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
amphotericin B - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Amphotericin B sodium - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
candicidin - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
CDRI-99288 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
D-121 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Drugs for Leishmaniasis and Trypanosomiasis - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
GNF-6702 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
hypoestoxide - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
interferon gamma - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
KVH-14 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
leishmaniasis vaccine - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
leishmaniasis vaccine - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
leishmaniasis vaccine - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
leishmaniasis vaccine - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
leishmaniasis vaccine 2 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
NPC-1161B - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
P-MAPA - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Peptides for Infectious Diseases - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
S-010269 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
SJL-01 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Small Molecule for Leishmaniasis - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Small Molecule for Leishmaniasis - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Small Molecule for Visceral Leishmaniasis - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Small Molecules for Infectious Diseases - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Small Molecules for Infectious Diseases - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Small Molecules for Leishmaniasis - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Small Molecules for Leishmaniasis - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
Small Molecules for Visceral Leishmaniasis - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Small Molecules for Visceral Leishmaniasis - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Small Molecules to Block LHR1 for Leishmaniasis - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease and Leishmaniasis - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Small Molecules to Inhibit Leishmania Major Casein Kinase 1 Isoform 2 for Leishmaniasis - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Small Molecules to Inhibit Nucleoside Hydrolase for Leishmaniasis - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Synthetic Peptides for Infectious Disease - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Vaccine for Leishmaniasis - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
visceral leishmaniasis vaccine - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Leishmaniasis (Kala-Azar) - Dormant Projects 90
Leishmaniasis (Kala-Azar) - Discontinued Products 92
Leishmaniasis (Kala-Azar) - Product Development Milestones 93
Featured News & Press Releases 93
Dec 15, 2015: U.S. Issues Patent on Corifungin 93
Oct 26, 2015: iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program 93
Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions 93
Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients 94
Feb 26, 2013: National Institutes of Health Supports Aceas Research 95
Mar 06, 2012: 10 million boost for neglected tropical disease research at Dundee 95
Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis 96
Oct 24, 2011: iCo Therapeutics Oral Amphotericin B Delivery System To Be Presented At AAPS 97
Jul 01, 2011: FDA issues orphan-drug designation to Corifungin 98
Sep 29, 2010: iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status 98
Feb 10, 2010: Dr. Jose Vazquez presents poster at ICAAC 99
Dec 14, 2005: Collaboration on the Development of Anti-Parasitic Drugs for Both Malaria and Leishmaniasis 99
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 101
Disclaimer 102

List of Tables
Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2016 11
Number of Products under Development for Leishmaniasis (Kala-Azar) - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Comparative Analysis by Unknown Stage Development, H2 2016 19
Products under Development by Companies, H2 2016 20
Products under Investigation by Universities/Institutes, H2 2016 21
Leishmaniasis (Kala-Azar) - Pipeline by Advinus Therapeutics Ltd, H2 2016 22
Leishmaniasis (Kala-Azar) - Pipeline by BioLingus AG, H2 2016 23
Leishmaniasis (Kala-Azar) - Pipeline by iCo Therapeutics Inc., H2 2016 24
Leishmaniasis (Kala-Azar) - Pipeline by Laboratorios LETI S.L., H2 2016 25
Leishmaniasis (Kala-Azar) - Pipeline by ManRos Therapeutics, H2 2016 26
Leishmaniasis (Kala-Azar) - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016 27
Leishmaniasis (Kala-Azar) - Pipeline by Nanomerics Ltd, H2 2016 28
Leishmaniasis (Kala-Azar) - Pipeline by Novartis AG, H2 2016 29
Leishmaniasis (Kala-Azar) - Pipeline by Oblita Therapeutics BVBA, H2 2016 30
Assessment by Monotherapy Products, H2 2016 31
Assessment by Combination Products, H2 2016 32
Number of Products by Stage and Target, H2 2016 34
Number of Products by Stage and Mechanism of Action, H2 2016 36
Number of Products by Stage and Route of Administration, H2 2016 38
Number of Products by Stage and Molecule Type, H2 2016 40
Leishmaniasis (Kala-Azar) - Dormant Projects, H2 2016 90
Leishmaniasis (Kala-Azar) - Dormant Projects (Contd..1), H2 2016 91
Leishmaniasis (Kala-Azar) - Discontinued Products, H2 2016 92

List of Figures
Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2016 11
Number of Products under Development for Leishmaniasis (Kala-Azar) - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Products, H2 2016 18
Assessment by Monotherapy Products, H2 2016 31
Number of Products by Top 10 Targets, H2 2016 33
Number of Products by Stage and Top 10 Targets, H2 2016 33
Number of Products by Top 10 Mechanism of Actions, H2 2016 35
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 35
Number of Products by Routes of Administration, H2 2016 37
Number of Products by Stage and Routes of Administration, H2 2016 37
Number of Products by Molecule Types, H2 2016 39
Number of Products by Stage and Molecule Types, H2 2016 39

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *